Compare i-80 Gold Corp. Common Shares (IAUX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
i-80 Gold Corp. Common Shares vs Sana Biotechnology Inc — how do they compare? i-80 Gold Corp. Common Shares trades at $1.45 (market cap $1.34B), while Sana Biotechnology Inc trades at $2.34 (market cap $719.96M). The key difference: i-80 Gold Corp. Common Shares is the larger of the two by market cap, and i-80 Gold Corp. Common Shares is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| IAUX | SANA | |
|---|---|---|
Market Cap | $1.34B | $719.96M |
Volume | 3,239,725 | 4,901,517 |
Sector | Basic Materials | Health |
52-Week High | $2.08 | $5.92 |
52-Week Low | $0.89 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $1.32B | $633.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
